Ann: US patent allowed for Sygenus for acne, page-5

I have a, mostly spidey sense good tingle, that the secretions side of the business/science may develop from the sleeping giant to at the least an equal pillar of health and profit.

RGS trades clearly under the radar. This is short term bad, if one doesn't have heaps of patience mixed strongly with discipline then sell now.

The science has been validated by AGC's buying $$$ in one form or another, specifically with regard to Progenza. This defines both the short term and mid term. It is good, it means: BUY.

The long term is unknowable (like everything in the future). Two roads appear: a) a world leader in its fields dovetailing very nicely with the demographics -- aging -- of the developed world, and; b) takeover (Boo).

OV